Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE. A Marketing Authorisation Application with the European Medicines Agency is also under regulatory review for approval NEW YORK, June 29, 2026 /PRNewswire/ -- Nuvation Bio (NYSE: NUVB), a global oncology company...
FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE. A Marketing Authorisation Application with the European Medicines Agency is also under regulatory review for approval NEW YORK, June 29, 2026 /PRNewswire/ -- Nuvation Bio (NYSE: NUVB), a global oncology company...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.